NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 270 filers reported holding NOVOCURE LTD in Q1 2020. The put-call ratio across all filers is 1.44 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $554,000 | -70.3% | 7,123 | -73.2% | 0.01% | -68.4% |
| Q2 2022 | $1,866,000 | -36.9% | 26,618 | -25.3% | 0.04% | -24.0% |
| Q1 2022 | $2,956,000 | -2.7% | 35,621 | -9.8% | 0.05% | 0.0% |
| Q4 2021 | $3,037,000 | -33.7% | 39,479 | +0.0% | 0.05% | -36.7% |
| Q3 2021 | $4,579,000 | -46.1% | 39,478 | +3.6% | 0.08% | -51.2% |
| Q2 2021 | $8,492,000 | +62.6% | 38,117 | -6.5% | 0.16% | +37.3% |
| Q1 2021 | $5,223,000 | -76.2% | 40,778 | -67.8% | 0.12% | -79.9% |
| Q4 2020 | $21,937,000 | +7.4% | 126,523 | -36.1% | 0.59% | -31.2% |
| Q3 2020 | $20,420,000 | +99.9% | 197,971 | +8.5% | 0.86% | +97.5% |
| Q2 2020 | $10,215,000 | +5.0% | 182,451 | +22.7% | 0.43% | -12.2% |
| Q1 2020 | $9,725,000 | +216.9% | 148,717 | +305.5% | 0.49% | +285.2% |
| Q4 2019 | $3,069,000 | +16.6% | 36,671 | -0.6% | 0.13% | +2.4% |
| Q3 2019 | $2,633,000 | – | 36,910 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 350,884 | $26,344,000 | 8.01% |
| HARTLINE INVESTMENT CORP/ | 318,109 | $23,884,000 | 3.27% |
| Deep Track Capital, LP | 550,000 | $41,294,000 | 2.92% |
| MORGAN JESS S & CO INC | 43,975 | $3,302,000 | 2.03% |
| Taylor Frigon Capital Management LLC | 46,376 | $3,482,000 | 1.09% |
| Darsana Capital Partners LP | 258,937 | $19,441,000 | 0.90% |
| Private Harbour Investment Management & Counsel, LLC | 13,562 | $1,018,000 | 0.81% |
| Rhenman & Partners Asset Management AB | 120,387 | $9,610,000 | 0.64% |
| COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $751,000 | 0.50% |
| Baillie Gifford | 9,615,168 | $721,906,000 | 0.40% |